Evidence map›Paper›PMID 33344904›Full record

ArticleACS pharmacology & translational science2020

A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs.

Kun Yang, Ying Zhang, Robert Chou, Lai Yeung, Simon Letarte, Rong-Sheng Yang, Xuanwen Li, Maribel Beaumont, Rico Gunawan, Douglas Richardson and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kun YangRegulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Ying ZhangBiologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Robert ChouBiologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Lai YeungRegulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Simon LetarteAnalytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Rong-Sheng YangAnalytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Xuanwen LiAnalytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Maribel BeaumontDiscovery Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 213 E Grand Avenue, South San Francisco, California 94080, United States.
Rico GunawanBiologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Douglas RichardsonAnalytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Shara DellatoreRegulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Eric WoolfRegulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 770 Sumneytown Pike, WP75B-300, West Point, Pennsylvania 19486, United States.
Yang XuRegulated Bioanalysis, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., 770 Sumneytown Pike, WP75B-300, West Point, Pennsylvania 19486, United States.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The robustness of good laboratory practice and clinical data is reliant upon a clear understanding of the bioanalytical assays. One of the most important components of ligand-binding based assays is critical reagents used to directly or indirectly measure biologic markers or signals. High quality, reproducible, sustainable critical reagents through the development lifecycle could avoid unnecessary rework, multiple validations, cross-validations, and ensure consistency of the data. Numerous analytical methods (UPLC-size exclusion chromatography, cation exchange chromatography, biacore/octet, and high-resolution mass spectrometry) have been evaluated by using current critical reagents. A comprehensive analytical toolbox of biochemical and biophysical methods has been employed to evaluate the quality of critical reagents and explore potential issues if there are any. Moving forward, this "tiered approach" of critical reagents characterization will be used not only to establish critical quality attributes for new reagents but also to evaluate stability in support of reagents recertification.

Identifiers

PMID33344904
PMCPMC7737325
OpenAlexW3094962851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.